Researchers identify blood-based biomarkers that could help personalize treatment for autoimmune diabetes
Researchers at Bar-Ilan University's Azrieli Faculty of Medicine have identified blood biomarkers that accurately predict which mice would respond to an experimental combination therapy for latent autoimmune diabetes in adults (LADA), a form of autoimmune diabetes that is frequently mistaken for type 2 diabetes. The findings, published in MedComm, also show that the treatment restored normal…
Researchers at Bar-Ilan University have discovered blood biomarkers that could help personalize treatment for a form of autoimmune diabetes known as latent autoimmune diabetes in adults (LADA). These biomarkers, identified in a mouse model, accurately predict which mice would respond to a combination therapy involving gamma-aminobutyric acid (GABA), sitagliptin and omeprazole.
In about 30% of treated mice, the therapy restored normal blood sugar levels and stimulated the regeneration of insulin-producing cells in the pancreas. Two cell-free RNA biomarkers, Adgrb1 and Chd5, distinguished between mice that responded to the treatment and those that did not. If validated in humans, these biomarkers could enable physicians to tailor treatment to individual patients, avoiding one-size-fits-all approaches.
The study also shed light on the mechanism of regeneration, suggesting that new insulin-producing beta cells formed through replication rather than preservation. While promising, further research is needed before this approach can be tested clinically.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
